Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-13

Clinical Trial Update: Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and pharmacokinetics of intravenous KAE609 in healthy subjects for malaria; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KAE609 (cipargamin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malaria | Phase 1 | Status: COMPLETED | Results posted: 2021-12-13